Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
RKV | CBOE Canada | CAD | Real-time | |
RKV | TSXV | CAD | Delayed |
Rakovina Therapeutics Inc. engages in the research and development of new cancer treatments based on novel series of small-molecule DNA-damage response inhibitors (DDRi). Its preclinical product pipeline include kt-2000, a next generation oral targeted small molecule PARP inhibitors; kt-3000, a bi-functional small-molecule drug candidate; and kt-4000, a DNA-damaging DDR inhibitors. Rakovina Therapeutics Inc. was formerly known as Vincero Capital Corp. The company is headquartered in Vancouver, Canada.Rakovina Therapeutics Inc operates as a subsidiary of NewGen Therapeutics, Inc.
Name | Age | Since | Title |
---|---|---|---|
Wang Shen | - | 2021 | Member of Scientific Advisory Board |
Neil Sankar | - | 2021 | Member of Scientific Advisory Board |
Jeffrey A. Bacha | 54 | - | Executive Chairman |
Leonard E. Post | 69 | 2021 | Member of Scientific Advisory Board |
Michael Liggett | 62 | 2021 | Independent Director |
Petra Hamerlik | - | 2023 | Member of Scientific Advisory Board |
Artem Cherkasov | - | 2023 | Senior AI, Medicinal Chemistry Advisor & Member of Scientific Advisory Board |
Dennis M. Brown | 74 | 2021 | Chairman of Scientific Advisory Board & Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review